All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the European School of Haematology (ESH) How I manage CAR-T Therapies and Bispecific Antibodies for my Patients conference, the Lymphoma Hub spoke to Catherine Thieblemont, Hôpital Saint-Louis, Paris, FR. We asked, How do we select a patient with relapsed/refractory diffuse large B-cell lymphoma for CAR-T cell therapy?
How do we select a patient with R/R DLBCL for CAR-T?
Thieblemont summarizes the three main criteria in patient selection. The first, she explains, involves evaluation of disease progression and evolution. For the second she highlights that age is not a barrier, as shown in the ZUMA-1 trial. Finally she explains the importance of evaluating organ function and comorbidities.
Why patients with large B-cell lymphoma fail CAR T-cell therapy & how to manage them
This article explores the potential reasons for relapse following CAR T-cell therapy and the management strategies for this population of large B-cell lymphoma...
Long-term outcomes of the ZUMA-1 study assessing axicabtagene ciloleucel for the treatment of refractory B-cell lymphoma
2-year activity and safety results of the ZUMA-1 trial investigating axicabtagene ciloleucel for refractory large B-cell lymphoma.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox